司库奇尤单抗
司库奇尤单抗（英语：Secukinumab），商品名为可善挺（英语：Cosentyx），是治疗干癣、僵直性脊椎炎和干癣性关节炎的药物[7]。以皮下注射给药[8]。
-0522.jpg) 诺华的可善挺（司库奇尤单抗）自动注射器（笔针） | |
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | 制介白素17A |
| 临床资料 | |
| 商品名 | Cosentyx |
| 其他名称 | AIN457 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615011 |
| 核准状况 | |
| 怀孕分级 |
|
| 给药途径 | 皮下注射或静脉注射 |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 |
|
| 识别信息 | |
| CAS号 | 875356-43-7（（重链） 875356-44-8 （轻链））  |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6584H10134N1754O2042S44 |
| 摩尔质量 | 147,944.37 g·mol−1 |
常见的副作用包括流鼻涕、腹泻、唇疱疹和荨麻疹[8]。其他副作用包括可能过敏和感染[8]。不建议在怀孕或哺乳期使用[9]。它是一种会结合并抑制介白素17A的单克隆抗体[8]。
参考文献
编辑- ^ Cosentyx (Novartis Pharmaceuticals Australia Pty Ltd). Therapeutic Goods Administration (TGA). 7 October 2022 [9 April 2023]. （原始内容存档于22 November 2022）.
- ^ Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. （原始内容存档于10 April 2023）.
- ^ Health Canada New Drug Authorizations: 2015 Highlights. 加拿大卫生部. 4 May 2016 [7 April 2024]. （原始内容存档于20 February 2020）.
- ^ Cosentyx 150mg and 300mg solution for injection in pre-filled syringe and pre-filled pen - Summary of Product Characteristics (SmPC). (emc). 6 June 2022 [9 November 2022]. （原始内容存档于3 October 2017）.
- ^ Cosentyx- secukinumab injection. DailyMed. 4 November 2022 [9 November 2022].
- ^ Cosentyx EPAR. European Medicines Agency (EMA). 17 September 2018 [7 May 2020]. （原始内容存档于22 August 2020）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 7.0 7.1 Cosentyx. [11 October 2021]. （原始内容存档于22 August 2020）.
- ^ 8.0 8.1 8.2 8.3 8.4 Secukinumab Monograph for Professionals. Drugs.com. [11 October 2021]. （原始内容存档于4 March 2021） （英语）.
- ^ BNF 80. BMJ Group and the Pharmaceutical Press. September 2020 - March 2021: 1162. ISBN 978-0-85711-369-6.
